Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07415070

Effectiveness of Targeted Cervical Length Screening Guided by a Preterm Birth Risk Scoring System in Reducing the Rate of Preterm Birth

This cluster non-randomized controlled trial aims to evaluate the effectiveness and feasibility of a risk score-guided targeted cervical length screening strategy for the prevention of spontaneous preterm birth in routine community-based prenatal care. Pregnant women are first assessed using a simple preterm birth risk scoring system, and those identified as high risk undergo transvaginal cervical length screening followed by guideline-based preventive interventions when clinically indicated.

The primary objective of the study is to compare this targeted screening strategy with usual prenatal care in reducing the incidence of spontaneous preterm birth occurring between 28 and 36 completed weeks of gestation. Secondary objectives include evaluating the cervical length screening rate, adherence to cervical length screening recommendations, and selected maternal and neonatal outcomes.

Researchers will compare outcomes between women receiving risk score-guided targeted screening and those receiving routine prenatal care without use of the risk scoring system. All participants will be followed until delivery.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ningbo University

Ningbo, Zhejiang, 315000, China

About this study

  • Preterm birth is a leading cause of neonatal mortality, and current guidelines mainly recommend cervical length screening for women with a prior history of preterm birth, leaving many high-risk women without such a history unidentified. This study applies a validated early-pregnancy (<14 weeks' gestation) preterm birth risk scoring system based on 17 routinely collected clinical indicators to enable targeted risk stratification (e.g., 15 points for a previous preterm birth, 6 points for age <20 years, 3 points for age ≥35 years, 7 points for age ≥40 years, 1 point for BMI <18.5 kg/m², 7 points for diabetes mellitus, 5 points for chronic hypertension, 4 points for hyperthyroidism and diastolic blood pressure≥90 mmHg, 3 points for systolic blood pressure≥140 mmHg, 2 points for anaemia, 1 point for systolic blood pressure 120-139 mmHg). Screening efficiency is quantified using the number needed to screen (NNS) to support pragmatic clinical decision-making and resource allocation. The trial evaluates the effectiveness of implementing this risk-based screening strategy in real-world community settings.
  • Given the comparable maternal demographic profiles, historical preterm birth rates, levels of maternal health management, and healthcare accessibility in Yinzhou and Beilun districts, this study adopts a non-randomised, community-based cluster parallel controlled design. The intervention is implemented in Yinzhou District, while the control group is constructed using contemporaneous, anonymised maternal healthcare records from Beilun District obtained from the Ningbo Municipal Health Information Platform, with all required institutional and administrative approvals in place. Baseline comparability assessment and the use of geographically distinct data sources are intended to minimise confounding and intervention contamination, enabling evaluation of the effectiveness and feasibility of a standardised cervical length screening strategy in community settings.
  • The intervention group, located in Yinzhou District of Ningbo, will undergo assessment using the preterm birth risk scoring system. Women with a score >6 will be classified as high-risk and undergo cervical length screening via transvaginal ultrasonography. Those with a cervical length ≤25 mm will receive guideline-based standardised preventive interventions as clinically indicated. The control group, located in Beilun District of Ningbo, will receive routine prenatal care according to current clinical practice, without risk score assessment.
  • Pregnant women identified by transvaginal ultrasonography as having a cervical length ≤25 mm will be referred, according to a predefined standardised care pathway, to tertiary hospitals with established maternal-fetal medicine (MFM) services for further evaluation and management. Final assessment will be conducted by senior MFM specialists in accordance with current clinical guidelines, followed by implementation of preventive interventions. Vaginal progesterone therapy will be initiated in women without relevant high-risk obstetric history, while cervical cerclage will be performed in those meeting specific indications, such as a history of spontaneous mid-trimester pregnancy loss or preterm birth.
  • Community health service centers in both districts will use standardized tools to collect participants' baseline characteristics, screening information, intervention implementation, and pregnancy outcome data. Participants will be followed up until delivery, with primary assessment of pregnancy outcomes, including spontaneous preterm birth, et al.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ·For community health service centers:
  • Be located in the selected districts
  • Provide prenatal care and be responsible for the registration and follow-up management of pregnant women
  • Have the chief physician (or equivalent) agree to participate and to implement study-related risk assessment, referral, follow-up, and data collection procedures, and to receive standardized training
  • For pregnant women:

<!-- -->

  • Registered at participating community health service centers.
  • Singleton pregnancy.
  • No history of previous cervical cerclage.
  • Able and willing to provide written informed consent and participate in the study.

Exclusion criteria

  • for pregnant women:
  • Multiple pregnancies.
  • History of cervical cerclage.
  • Medical indications requiring pregnancy termination.
  • Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.

Treatment and study plan

Preterm birth risk scoring system

Other

Assessment using the validated preterm birth risk scoring system in early pregnancy to stratify women into risk categories.

Transvaginal ultrasound cervical length measurement

Device

Women identified as high risk by the preterm birth risk scoring system will undergo transvaginal ultrasound measurement of cervical length during the mid-trimester (16-24 weeks of gestation).

vaginal progesterone

Drug

Administration of vaginal progesterone for women with cervical length ≤25 mm, according to guideline-based management.

Cervical cerclage

Procedure

Placement of cervical cerclage for women meeting established clinical guideline criteria.

Primary outcomes

  1. Preterm birth rate

    Time frame: At delivery.

    Proportion of enrolled pregnant women who deliver between 28 and 36 +6 weeks of gestation, based on pregnancy outcome records. The rate of preterm birth will be compared between the intervention group and the control group based on pregnancy outcome records.

Secondary outcomes

  1. Incidence of extremely preterm

    Time frame: At delivery.

    Proportion of spontaneous preterm births occurring before 28 weeks of gestation.

  2. Incidence of very preterm

    Time frame: At delivery.

    Proportion of spontaneous preterm births occurring between 28 and 31+6 weeks of gestation.

  3. Incidence of moderate-to-late preterm

    Time frame: At delivery.

    Proportion of spontaneous preterm births occurring between 32 and 36+6 weeks of gestation.

  4. Cervical length screening rate

    Time frame: At mid-trimester (16-24 gestational weeks).

    Proportion of all enrolled pregnant women who undergo transvaginal cervical length screening as recommended by the study protocol.

  5. Adherence to cervical length screening

    Time frame: At mid-trimester (16-24 gestational weeks).

    Proportion of women classified as high risk by the preterm birth risk score who undergo transvaginal cervical length measurement as recommended.

  6. Adherence to preventive treatment

    Time frame: Up to 42 weeks of gestation.

    Proportion of pregnant women with a cervical length ≤25mm who received guideline-recommended preventive interventions (e.g., vagina progesterone, or other standardized management).

  7. Neonatal birth weight

    Time frame: At birth.

    Birth weight of the newborn, obtained from delivery records and recorded in grams.

  8. Rate of neonatal intensive care unit (NICU) admission

    Time frame: Within the first 28 days of life (neonatal period).

    Admission of the newborn to the neonatal intensive care unit following delivery.

Sponsors and collaborators

Lead sponsor

Ningbo University

Other

Collaborators

  • The Affiliated Ningbo Women and Children's Hospital of Ningbo University
  • Yinzhou District Maternal and Child Health Care Hospital, Ningbo

Registry information

Official study title

Effectiveness of Targeted Cervical Length Screening Guided by a Preterm Birth Risk Scoring System in Reducing the Rate of Preterm Birth: a Cluster Non-randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 17, 2026
Registry last updated
Feb 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.